AstraZeneca

Top 10 pharma R&D budgets in 2022
Top 10 pharma R&D budgets in 2022
Fierce Biotech
R&D
Roche
JNJ
Merck
Pfizer
Novartis
AstraZeneca
Bristol Myers Squibb
Eli Lilly
Sanofi
AbbVie
Flag link:
AstraZeneca stays on course to challenge Alnylam with 66-week rare disease data
AstraZeneca stays on course to challenge Alnylam with 66-week rare disease data
Fierce Biotech
AstraZeneca
Ionis Pharmaceuticals
aplontersen
Alnylam
Onpattro
clinical trials
ATTRv-PN
Flag link:
Lazertinib and Tagrisso go head to head
Lazertinib and Tagrisso go head to head
EP Vantage
AstraZeneca
lazertinib
Tagrisso
JNJ
lung cancer
Flag link:
AACR 2023 – Moderna's immunotherapeutic splash
AACR 2023 – Moderna's immunotherapeutic splash
EP Vantage
AACR
Moderna Therapeutics
Allogene
AstraZeneca
Merck
Roche
Novartis
Eli Lilly
Innovent
Springworks
Biogene
Relay Therapeutics
Vivace Therapeutics
Flag link:
AstraZeneca employees fight layoffs in India as drugmaker shifts 'strategic priorities'
AstraZeneca employees fight layoffs in India as drugmaker shifts 'strategic priorities'
Fierce Pharma
AstraZeneca
layoffs
India
Flag link:
AstraZeneca says cancer drug Imfinzi improves survival chances in late-stage trial
AstraZeneca says cancer drug Imfinzi improves survival chances in late-stage trial
Reuters
AstraZeneca
Imfinzi
lung cancer
Flag link:
Tagrisso reaches OS endpoint in PhIII EGFR-mutated lung cancer trial
Tagrisso reaches OS endpoint in PhIII EGFR-mutated lung cancer trial
Endpoints
AstraZeneca
lung cancer
clinical trials
Tagrisso
Flag link:
AstraZeneca draws back the curtains on its leadership team, launches new podcast
AstraZeneca draws back the curtains on its leadership team, launches new podcast
Fierce Pharma
AstraZeneca
executives
podcast
Flag link:
AstraZeneca, Daiichi Sankyo tease new Enhertu data — but details remain under wraps
AstraZeneca, Daiichi Sankyo tease new Enhertu data — but details remain under wraps
Endpoints
AstraZeneca
Daiichi Sankyo
Enhertu
clinical trials
Flag link:
FDA asks advisers to review Lynparza amid growing scrutiny of PARP drugs
FDA asks advisers to review Lynparza amid growing scrutiny of PARP drugs
BioPharma Dive
Merck
AstraZeneca
Lynparza
FDA
PARP inhibitors
Flag link:
AstraZeneca, Merck's Lynparza to face FDA panel in prostate cancer bid as PARP scrutiny escalates
AstraZeneca, Merck's Lynparza to face FDA panel in prostate cancer bid as PARP scrutiny escalates
Fierce Pharma
AstraZeneca
Merck
Lynparza
FDA
prostate cancer
Flag link:
Go or no go? Vaccines and neurology up for discussion
Go or no go? Vaccines and neurology up for discussion
EP Vantage
FDA
Acadia Pharmaceuticals
Apellis Pharmaceuticals
AstraZeneca
Biogen
Biomarin
Cidara Therapeutics
Emergent BioSolutions
GSK
Incyte
Ionis Pharmaceuticals
Melinta Therapeutics
Mundipharma
Novartis
Pfizer
Pharming
Regeneron
Roche
vaccines
RSV
ALS
COVID-19
Flag link:
AstraZeneca expands Canada R&D work, to add 500 jobs
AstraZeneca expands Canada R&D work, to add 500 jobs
Endpoints
AstraZeneca
Canada
hirings
R&D
Flag link:
AstraZeneca pulls back the corporate curtain to highlight real people and chat complex science
AstraZeneca pulls back the corporate curtain to highlight real people and chat complex science
Endpoints
AstraZeneca
social media
Flag link:
AstraZeneca strengthens its oncology R&D with in-licensing of CMG901 from China-based biotech KYM Biosciences
AstraZeneca strengthens its oncology R&D with in-licensing of CMG901 from China-based biotech KYM Biosciences
Medical Marketing and Media
AstraZeneca
CMG901
antibody-drug conjugate
gastric cancer
KYM Biosciences
Flag link:
AstraZeneca doubles down on hot cancer target, paying $63M for ADC months after bispecific deal
AstraZeneca doubles down on hot cancer target, paying $63M for ADC months after bispecific deal
Fierce Biotech
AstraZeneca
Claudin18.2
KYM Biosciences
antibody-drug conjugate
pancreatic cancer
Flag link:
Pfizer's maternal RSV vaccine filing gets priority review, setting up showdown with AstraZeneca, Sanofi
Pfizer's maternal RSV vaccine filing gets priority review, setting up showdown with AstraZeneca, Sanofi
Fierce Pharma
Pfizer
RSV
vaccines
GSK
AstraZeneca
Sanofi
RSVpreF
Flag link:
First FDA-Approved RSV Vaccines Expected Later This Year: The Top Vaccines And Their Effectiveness
First FDA-Approved RSV Vaccines Expected Later This Year: The Top Vaccines And Their Effectiveness
Forbes
RSV
vaccines
GSK
Pfizer
Sanofi
Sobi
Moderna Therapeutics
AstraZeneca
JNJ
FDA
Flag link:
Faced with safety issues over inflammation drug, AstraZeneca spinout Aristea closes shop
Faced with safety issues over inflammation drug, AstraZeneca spinout Aristea closes shop
Fierce Biotech
Aristea Therapeutics
AstraZeneca
Flag link:
AstraZeneca CEO Pascal Soriot aims for 15 new drug launches by 2030
AstraZeneca CEO Pascal Soriot aims for 15 new drug launches by 2030
Endpoints
AstraZeneca
drug launches
Pascal Soriot
Pharma CEOs
Flag link:

Pages